Literature DB >> 22056842

Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.

Samia Ben Sassi1, Fatma Nabli, Emna Hentati, Houda Nahdi, Meriam Trabelsi, Hela Ben Ayed, Rim Amouri, John Eric Duda, Matthew John Farrer, Fayçal Hentati.   

Abstract

BACKGROUND: Cognitive impairment and dementia are frequent and debilitating features associated with idiopathic Parkinson's disease (PD). However the prevalence and the pattern of these complications are lacking for LRRK2 (leucine-rich kinase 2)-associated PD patients.
PURPOSE: The purpose of this study was to assess cognitive function in LRRK2- associated PD patients.
MATERIAL AND METHODS: 55 patients diagnosed with PD-related LRRK2 G2019S mutation were included in the study and compared to the same number of G2019S non-carriers PD patients. Age, sex, disease duration, the movement disorder society-unified Parkinson's Disease rating scale (MDS-UPDRS), Hoehn and Yahr stage, Schwab and England scale and the 30-item geriatric depression scale (GDS) scores were noted. Cognitive assessment included MMSE (Mini-Mental Examination), MOCA (Montreal Cognitive Assessment) and FAB (Frontal Assessment Battery).
RESULTS: MMSE, MOCA and FAB performance in G2019S carriers PD patients was similar to that of non-carriers. In both groups, performance was primarily impaired on visuospatial and executive tasks. Cognitive impairment was associated with older age, lower educational level and increased severity of motor impairment.
CONCLUSION: Cognitive functions were similarly affected in PD patients with and without LRRK2 G2019S mutation with mainly impaired visuospatial and executive abilities. However, these results need to be confirmed by further large and prospective studies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056842     DOI: 10.1016/j.parkreldis.2011.10.009

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  14 in total

1.  Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.

Authors:  Steven A Gunzler; David E Riley; Shu G Chen; Curtis M Tatsuoka; William M Johnson; John J Mieyal; Ellen M Walter; Christina M Whitney; I Jung Feng; Harry Owusu-Dapaah; Shivam O Mittal; Amy L Wilson-Delfosse
Journal:  J Neurol Sci       Date:  2018-03-17       Impact factor: 3.181

2.  Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Anat Mirelman; Rachel Saunders-Pullman; Deborah Raymond; Christina Palmese; Elise Caccappolo; Laurie Ozelius; Avi Orr-Urtreger; Lorraine Clark; Nir Giladi; Susan Bressman; Karen Marder
Journal:  Parkinsonism Relat Disord       Date:  2014-11-20       Impact factor: 4.891

Review 3.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

4.  A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis.

Authors:  Nir Giladi; Anat Mirelman; Avner Thaler; Avi Orr-Urtreger
Journal:  Front Neurol       Date:  2016-05-10       Impact factor: 4.003

Review 5.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

6.  Cognitive profile of LRRK2-related Parkinson's disease.

Authors:  Sindhu Srivatsal; Brenna Cholerton; James B Leverenz; Zbigniew K Wszolek; Ryan J Uitti; Dennis W Dickson; Daniel Weintraub; John Q Trojanowski; Vivianna M Van Deerlin; Joseph F Quinn; Kathryn A Chung; Amie L Peterson; Stewart A Factor; Cathy Wood-Siverio; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Beate Ritz; Rebecca Rausch; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Ignacio F Mata; Shu-Ching Hu; Kathleen S Montine; Catherine Johnson; Thomas J Montine; Karen L Edwards; Jing Zhang; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

7.  Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.

Authors:  Tanya Simuni; Michael C Brumm; Liz Uribe; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; Roy N Alcalay; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Kelly Nudelman; Duygu Tosun-Turgut; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha Hutten; Susan Bressman; Kenneth Marek
Journal:  Mov Disord       Date:  2020-02-19       Impact factor: 10.338

8.  DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.

Authors:  Moran Artzi; Einat Even-Sapir; Hedva Lerman Shacham; Avner Thaler; Avi Orr Urterger; Susan Bressman; Karen Marder; Talma Hendler; Nir Giladi; Dafna Ben Bashat; Anat Mirelman
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

9.  LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.

Authors:  Max Sloan; Javier Alegre-Abarrategui; Dawid Potgieter; Anna-Kristin Kaufmann; Richard Exley; Thierry Deltheil; Sarah Threlfell; Natalie Connor-Robson; Katherine Brimblecombe; Rebecca Wallings; Milena Cioroch; David M Bannerman; J Paul Bolam; Peter J Magill; Stephanie J Cragg; Paul D Dodson; Richard Wade-Martins
Journal:  Hum Mol Genet       Date:  2016-01-06       Impact factor: 6.150

10.  Clinical Heterogeneity Among LRRK2 Variants in Parkinson's Disease: A Meta-Analysis.

Authors:  Li Shu; Yuan Zhang; Hongxu Pan; Qian Xu; Jifeng Guo; Beisha Tang; Qiying Sun
Journal:  Front Aging Neurosci       Date:  2018-09-19       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.